
    
      The study is designed to determine the metabolic changes, antiviral activity, safety, and
      tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides,
      over the initial 24 weeks, with a final analysis at 48 weeks.
    
  